All In Biotech

BLA 103000 · Allergan

Botox Cosmetic

Onabotulinumtoxina · Single-Use · Acetylcholine Release Inhibitor; Neuromuscular Blocker

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Dec 9, 1991

Approved uses

25

Original approval plus efficacy supplements

Registered trials

1,077

324 Phase 3, 72 recruiting

FAERS reports

77,970

15,443 serious, 2,225 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to the se symptoms. In unapproved uses and in approved indications, cases of spread of effect...

What it is approved for

From the label in effect Feb 2, 2026.

BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) 1.1 Adult Bladder Dysfunction Overactive Bladder BOTOX for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency, in...

Mechanism: BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or autonomic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, BOTOX produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • BOTOX COSMETIC · OnabotulinumtoxinA 100 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
  • BOTOX · OnabotulinumtoxinA 200 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
  • BOTOX · OnabotulinumtoxinA 50 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
  • BOTOX COSMETIC · OnabotulinumtoxinA 50 UNITS/VIAL · VIAL, SINGLE-USE · Prescription
  • BOTOX · OnabotulinumtoxinA 100 UNITS/VIAL · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Onabotulinumtoxina" as an intervention, any sponsor and status, largest first.

All 1,077 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective26,774
  • off label use11,721
  • therapeutic response decreased4,513
  • headache4,135
  • product preparation error3,646
  • injection site pain3,468
  • eyelid ptosis3,149
  • multiple use of single-use product2,866
  • migraine2,406
  • nausea2,245
  • pain1,921
  • fatigue1,878

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004102
2005102
2006110
2007146
2008454
2009341
20104,860
20111,455
20122,710
20133,065
20143,096
20153,398
20164,998
20174,233
20184,692
20196,167
20205,224
20215,623
20225,185
20237,533
20245,357
20255,319
20263,800

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Botox (Onabotulinumtoxina)

2024 spending

$122M

Beneficiaries

35,913

90,229 claims

Per beneficiary

$3,405

$1,034.36 per unit

View as table
YearSpending
2020$58,026,492
2021$68,468,938
2022$90,961,370
2023$112,400,196
2024$122,282,695

Part B: Botox* (Onabotulinumtoxina*) · HCPCS J0585

2024 spending

$479M

Beneficiaries

165,103

403,331 claims

Per beneficiary

$2,899

2024 ASP limit $6.36 per unit

View as table
YearSpending
2020$330,751,077
2021$366,441,061
2022$414,805,768
2023$444,518,571
2024$478,583,956

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 424 on PubMed

Sponsor: AbbVie · Also marketed as Botox

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.